

**TOXICOLOGICAL PROFILE FOR
4,4'-METHYLENEBIS(2-CHLOROANILINE) MBOCA**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Agency for Toxic Substances and Disease Registry**

May 1994

DISCLAIMER

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

UPDATE STATEMENT

Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology/Toxicology Information Branch
1600 Clifton Road NE, E-29
Atlanta, Georgia 30333

FOREWORD

The Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99-499) extended and amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed the Agency for Toxic Substances and Disease Registry (ATSDR) to prepare toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the Environmental Protection Agency (EPA). The revised list of the 275 most hazardous substances was published in the Federal Register on October 28, 1992 (57 FR 48801). For prior versions of the list of substances, see Federal Register notices dated April 17, 1987 (52 FR 12866); October 20, 1988 (53 FR 41280); October 26, 1989 (54 FR 43619); October 17, 1990 (55 FR 42067); and October 17, 1991 (56 FR 52166).

Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. Each profile must include the following:

- (A) The examination, summary, and interpretation of available toxicological information and epidemiological evaluations on a hazardous substance in order to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects.
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects.
- (C) Where appropriate, identification of toxicological testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

This toxicological profile is prepared in accordance with guidelines developed by ATSDR and EPA. The original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile is intended to succinctly characterize the toxicological and adverse health effects information for the hazardous substance being described. Each profile identifies and reviews the key literature (that has been peer-reviewed) that describes a hazardous substance's toxicological properties. Other pertinent literature is also presented, but described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

Each toxicological profile begins with a public health statement, that describes in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protect public health will be identified by ATSDR and EPA. The focus of the profiles is on health and toxicological information; therefore, we have included this information in the beginning of the document.

Foreword

The principal audiences for the toxicological profiles are health professionals at the federal, state, and local levels, interested private sector organizations and groups, and members of the public.

This profile reflects our assessment of all relevant toxicological testing and information that has been peer reviewed. It has been reviewed by scientists from ATSDR, the Centers for Disease Control and Prevention (CDC), and other federal agencies. It has also been reviewed by a panel of nongovernment peer reviewers and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



David Satcher, M.D., Ph.D.
Administrator
Agency for Toxic Substances and
Disease Registry

CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHOR(S):

Penny Duerksen-Hughes, Ph.D.
ATSDR, Division of Toxicology, Atlanta, GA

Vera Brankovan, Ph.D.
Clement International Corporation

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Green Border Review. Green Border Review assures the consistency with ATSDR policy.
2. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
3. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-related minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
4. Quality Assurance Review. The Quality Assurance Branch assures that consistency across profiles is maintained, identifies any significant problems in format or content, and establishes that Guidance has been followed.

PEER REVIEW

A peer review panel was assembled for MBOCA. The panel consisted of the following members:

1. Dr. W. Emmett Braselton, Jr., Professor of Pharmacology/Toxicology, Michigan State University, East Lansing, Michigan.
2. Dr. Arthur Gregory, private consultant, Techto Enterprises, Sterling, Virginia.
3. Dr. Fumio Matsumura, Assistant Director of Toxic Substances Program, Institute of Toxicology and Environmental Health, University of California, Davis, California.

These experts collectively have knowledge of MBOCA's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(i)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound. A list of databases reviewed and a list of unpublished documents cited are also included in the administrative record.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.

CONTENTS

UPDATE STATEMENT	iii
FOREWORD	v
CONTRIBUTORS	vii
PEER REVIEW	ix
LIST OF FIGURES	xv
LIST OF TABLES	xvii
1. PUBLIC HEALTH STATEMENT	1
1.1 WHAT IS MBOCA?	1
1.2 WHAT HAPPENS TO MBOCA WHEN IT ENTERS THE ENVIRONMENT?	1
1.4 HOW CAN MBOCA ENTER AND LEAVE MY BODY?	2
1.5 HOW CAN MBOCA AFFECT MY HEALTH?	2
1.6 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO MBOCA?	3
1.7 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH?	3
1.8 WHERE CAN I GET MORE INFORMATION?	3
2. HEALTH EFFECTS	5
2.1 INTRODUCTION	5
2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE	5
2.2.1 Inhalation Exposure	6
2.2.1.1 Death	7
2.2.1.2 Systemic Effects	7
2.2.1.3 Immunological Effects	8
2.2.1.4 Neurological Effects	8
2.2.1.5 Reproductive Effects	8
2.2.1.6 Developmental Effects	8
2.2.1.7 Genotoxic Effects	8
2.2.1.8 Cancer	8
2.2.2 Oral Exposure	9
2.2.2.1 Death	9
2.2.2.2 Systemic Effects	9
2.2.2.3 Immunological Effects	11
2.2.2.4 Neurological Effects	11
2.2.2.5 Reproductive Effects	12
2.2.2.6 Developmental Effects	12
2.2.2.7 Genotoxic Effects	12
2.2.2.8 Cancer	13
2.2.3 Dermal Exposure	21

2.2.3.1	Death	21
2.2.3.2	Systemic Effects	21
2.2.3.3	Immunological Effects	22
2.2.3.4	Neurological Effects	22
2.2.3.5	Reproductive Effects	22
2.2.3.6	Developmental Effects	22
2.2.3.7	Genotoxic Effects	22
2.2.3.8	Cancer	22
2.3	TOXICOKINETICS	23
2.3.1	Absorption	25
2.3.1.1	Inhalation Exposure	25
2.3.1.2	Oral Exposure	26
2.3.1.3	Dermal Exposure	26
2.3.2	Distribution	27
2.3.2.1	Inhalation Exposure	27
2.3.2.2	Oral Exposure	27
2.3.2.3	Dermal Exposure	28
2.3.2.4	Other Routes of Exposure	28
2.3.3	Metabolism	28
2.3.3.1	Inhalation Exposure	29
2.3.3.2	Oral Exposure	29
2.3.3.3	Dermal Exposure	30
2.3.4	Excretion	31
2.3.4.1	Inhalation Exposure	31
2.3.4.2	Oral Exposure	32
2.3.4.3	Dermal Exposure	33
2.3.4.4	Other Routes of Exposure	34
2.3.5	Mechanisms of Action	35
2.4	RELEVANCE TO PUBLIC HEALTH	36
2.5	BIOMARKERS OF EXPOSURE AND EFFECT	48
2.5.1	Biomarkers Used to Identify or Quantify Exposure to MBOCA	49
2.5.2	Biomarkers Used to Characterize Effects Caused by MBOCA	49
2.6	INTERACTIONS WITH OTHER CHEMICALS	50
2.7	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	50
2.8	METHODS FOR REDUCING TOXIC EFFECTS	51
2.8.1	Reducing Peak Absorption Following Exposure	51
2.8.2	Reducing Body Burden	52
2.8.3	Interfering with the Mechanism of Action for Toxic Effects	53
2.9	ADEQUACY OF THE DATABASE	53
2.9.1	Existing Information on Health Effects of MBOCA	53
2.9.3	On-going Studies	59
3.	CHEMICAL AND PHYSICAL INFORMATION	61
3.1	CHEMICAL IDENTITY	61
3.2	PHYSICAL AND CHEMICAL PROPERTIES	61
4.	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	65
4.1	PRODUCTION	65

4.2	IMPORT/EXPORT	65
4.3	USE	65
4.4	DISPOSAL	67
5.	POTENTIAL FOR HUMAN EXPOSURE	69
5.1	OVERVIEW	69
5.2	RELEASES TO THE ENVIRONMENT	69
5.2.1	Air	69
5.2.2	Water	69
5.2.3	Soil	69
5.3	ENVIRONMENTAL FATE	72
5.3.1	Transport and Partitioning	72
5.3.2	Transformation and Degradation	72
5.3.2.1	Air	72
5.3.2.2	Water	72
5.3.2.3	Sediment and Soil	73
5.4	LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT	73
5.4.1	Air	73
5.4.2	Water	74
5.4.3	Sediment and Soil	74
5.4.4	Other Environmental Media	74
5.5	GENERAL POPULATION AND OCCUPATIONAL EXPOSURE	74
5.6	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	76
5.7	ADEQUACY OF THE DATABASE	76
5.7.1	Identification of Data Needs	76
5.7.2	On-going Studies	78
6.	ANALYTICAL METHODS	79
6.1	BIOLOGICAL MATERIALS	79
6.2	ENVIRONMENTAL SAMPLES	86
6.3	ADEQUACY OF THE DATABASE	91
6.3.1	Identification of Data Needs	91
6.3.2	On-going Studies	92
7.	REGULATIONS AND ADVISORIES	93
8.	REFERENCES	97
9.	GLOSSARY	117
APPENDICES		
A.	USER'S GUIDE	A-1
B.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS	B-1

LIST OF FIGURES

2-1 Levels of Significant Exposure to MBOCA - Oral	20
2-2 Proposed Metabolic Pathway of MBOCA	24
2-3 Existing Information on Health Effects of MBOCA	54
5-1 Frequency of NPL Sites with MBOCA Contamination	70

LIST OF TABLES

2-1	Levels of Significant Exposure to MBOCA - Oral	16
2-2	Genotoxicity of MBOCA <i>In Vivo</i>	41
2-3	Genotoxicity of MBOCA <i>In Vitro</i>	42
3-1	Chemical Identity of MBOCA	62
3-2	Physical and Chemical Properties of MBOCA	63
4-1	Facilities That Manufacture or Process MBOCA	66
5-1	Releases to the Environment from Facilities That Manufacture or Process MBOCA	71
6-1	Analytical Methods for Determining MBOCA in Biological Materials	80
6-2	Analytical Methods for Determining MBOCA in Environmental Samples	87
7-1	Regulations and Guidelines Applicable to MBOCA	94

